Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Subscribe To Our Newsletter & Stay Updated
